These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25007399)

  • 1. [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for in vivo targeting of somatostatin receptor-positive tumors.
    Maina T; Cescato R; Waser B; Tatsi A; Kaloudi A; Krenning EP; de Jong M; Nock BA; Reubi JC
    J Med Chem; 2014 Aug; 57(15):6564-71. PubMed ID: 25007399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [111In-DOTA]Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    EJNMMI Res; 2012 Jun; 2(1):25. PubMed ID: 22682002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fish somatostatin sst3 receptor: comparison of radioligand and GTPgammaS binding, adenylate cyclase and phospholipase C activities reveals different agonist-dependent pharmacological signatures.
    Siehler S; Nunn C; Zupanc GK; Hoyer D
    Auton Autacoid Pharmacol; 2005 Jan; 25(1):1-16. PubMed ID: 15659149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.
    Ginj M; Zhang H; Eisenwiener KP; Wild D; Schulz S; Rink H; Cescato R; Reubi JC; Maecke HR
    Clin Cancer Res; 2008 Apr; 14(7):2019-27. PubMed ID: 18381940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of human recombinant somatostatin receptors. 4. Modulation of phospholipase C activity.
    Siehler S; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):522-32. PubMed ID: 10598791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.
    Tatsi A; Maina T; Cescato R; Waser B; Krenning EP; de Jong M; Cordopatis P; Reubi JC; Nock BA
    Eur J Med Chem; 2014 Feb; 73():30-7. PubMed ID: 24378707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of the fish sst3 receptor, a member of the SRIF1 receptor family: atypical pharmacological features.
    Siehler S; Zupanc GK; Seuwen K; Hoyer D
    Neuropharmacology; 1999 Mar; 38(3):449-62. PubMed ID: 10219983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
    Wild D; Schmitt JS; Ginj M; Mäcke HR; Bernard BF; Krenning E; De Jong M; Wenger S; Reubi JC
    Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1338-47. PubMed ID: 12937948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterisation of human recombinant somatostatin receptors. 2. Modulation of GTPgammaS binding.
    Siehler S; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):500-9. PubMed ID: 10598789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatostatin receptor-binding peptides suitable for tumor radiotherapy with Re-188 or Re-186. Chemistry and initial biological studies.
    Cyr JE; Pearson DA; Wilson DM; Nelson CA; Guaraldi M; Azure MT; Lister-James J; Dinkelborg LM; Dean RT
    J Med Chem; 2007 Mar; 50(6):1354-64. PubMed ID: 17315859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists.
    Cescato R; Schulz S; Waser B; Eltschinger V; Rivier JE; Wester HJ; Culler M; Ginj M; Liu Q; Schonbrunn A; Reubi JC
    J Nucl Med; 2006 Mar; 47(3):502-11. PubMed ID: 16513620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue.
    Antunes P; Ginj M; Walter MA; Chen J; Reubi JC; Maecke HR
    Bioconjug Chem; 2007; 18(1):84-92. PubMed ID: 17226960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [125I][Tyr3]octreotide labels human somatostatin sst2 and sst5 receptors.
    Siehler S; Seuwen K; Hoyer D
    Eur J Pharmacol; 1998 May; 348(2-3):311-20. PubMed ID: 9652348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of human recombinant somatostatin receptors. 1. Radioligand binding studies.
    Siehler S; Seuwen K; Hoyer D
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Nov; 360(5):488-99. PubMed ID: 10598788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation.
    Roosenburg S; Laverman P; Joosten L; Eek A; Oyen WJ; de Jong M; Rutjes FP; van Delft FL; Boerman OC
    Bioconjug Chem; 2010 Apr; 21(4):663-70. PubMed ID: 20302291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive evaluation of a somatostatin-based radiolabelled antagonist for diagnostic imaging and radionuclide therapy.
    Wang X; Fani M; Schulz S; Rivier J; Reubi JC; Maecke HR
    Eur J Nucl Med Mol Imaging; 2012 Dec; 39(12):1876-85. PubMed ID: 22926735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy.
    Smith-Jones PM; Bischof C; Leimer M; Gludovacz D; Angelberger P; Pangerl T; Peck-Radosavljevic M; Hamilton G; Kaserer K; Kofler A; Schlangbauer-Wadl H; Traub T; Virgolini I
    Endocrinology; 1999 Nov; 140(11):5136-48. PubMed ID: 10537142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo comparison of human Escherichia coli heat-stable peptide analogues incorporating the 111In-DOTA group and distinct linker moieties.
    Giblin MF; Gali H; Sieckman GL; Owen NK; Hoffman TJ; Forte LR; Volkert WA
    Bioconjug Chem; 2004; 15(4):872-80. PubMed ID: 15264876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of 111In-DOTA-NOC and 111I-DOTA-TATE distribution in the target and dose-limiting tissues: conflicting results in vitro and in vivo.
    Cihlo J; Melicharová L; Petrik M; Laznickova A; Laznicek M
    Anticancer Res; 2008; 28(4B):2189-95. PubMed ID: 18751394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.